Carbazole scaffolds in cancer therapy: a review from 2012 to 2018. (1st January 2019)

• Record Type: Journal Article
• Authors: Issa, Samar; Prandina, Anthony; Bedel, Nicolas; Rongved, Pål; Yous, Saïd; Le Borgne, Marc; Bouaziz, Zouhair
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 34:Number 1(2019)
• Page Start: 1321
• Page End: 1346
• Publication Date: 2019-01-01
• Subjects: Carbazole -- cancer -- cytotoxicity -- targeted therapy -- enzyme inhibitors; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.1080/14756366.2019.1640692
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic–carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.